Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas

2015 ◽  
Vol 57 (12) ◽  
pp. 1269-1280 ◽  
Author(s):  
Francesca Piludu ◽  
Simona Marzi ◽  
Andrea Pace ◽  
Veronica Villani ◽  
Alessandra Fabi ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Antiangiogenic Therapy ◽  
High Grade ◽  
Resonance Imaging ◽  
Early Biomarkers ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced ◽  
High Grade Gliomas

scholarly journals RA-02DIFFUSION-WEIGHTED AND DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING AS MARKERS OF CLINICAL BEHAVIOUR IN PAEDIATRIC HIGH GRADE GLIOMAS

2016 ◽  
Vol 18 (suppl 3) ◽  
pp. iii165.1-iii165
Author(s):  
Fernando Carceller ◽  
Neil Jerome ◽  
Keiko Miyazaki ◽  
Matthew Orton ◽  
James d'Arcy ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
High Grade ◽  
Resonance Imaging ◽  
Dynamic Contrast Enhanced ◽  
Clinical Behaviour ◽  
Contrast Enhanced ◽  
High Grade Gliomas

Use of Magnetic Resonance Imaging to Assess Blood-Brain/Blood-Glioma Barrier Opening During Conformal Radiotherapy

2005 ◽  
Vol 23 (18) ◽  
pp. 4127-4136 ◽  
Author(s):  
Yue Cao ◽  
Christina I. Tsien ◽  
Zhou Shen ◽  
Daniel S. Tatro ◽  
Randall Ten Haken ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Conformal Radiotherapy ◽  
High Grade ◽  
Resonance Imaging ◽  
Blood Brain ◽  
Contrast Enhanced ◽  
Tumor Region ◽  
Region Contrast ◽  
High Grade Gliomas

Purpose For chemotherapy to act synergistically and safely with radiation against high-grade gliomas, drugs must pass the endothelial junctions of the blood-tumor barrier (BTB) to reach all tumor cells, and should not pass the blood-brain barrier (BBB) to cause toxicity to normal brain. The objective of this study was to assess BBB/BTB status using magnetic resonance imaging (MRI) during a course of radiotherapy of high-grade gliomas. Patients and Methods Sixteen patients with grade 3 or 4 supratentorial malignant glioma receiving conformal radiotherapy (RT) underwent contrast-enhanced MRI before, during, and after completion of RT. A gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) uptake index was analyzed with respect to the tumor and RT dose received. Results In the nonenhanced tumor region, contrast uptake increased significantly after the receipt of approximately 10 Gy (P < .01), and reached a maximum after the receipt of approximately 30 Gy. In the initially contrast-enhanced tumor region, contrast uptake decreased over the course of RT and became significant after completion of RT in patients without progressive disease. The healthy brain showed only nonsignificant changes during and after irradiation. Conclusion Contrast MRI reveals increases in Gd-DTPA uptake in the initially nonenhanced tumor region but not in the remaining brain during the course of RT, suggesting opening of the BTB. This finding suggests that the effect of conformal radiation is more selective on the BTB than the BBB, and there may be a window extending from 1 week after the initiation of radiotherapy to 1 month after the completion of treatment during which a pharmaceutical agent has maximum access to high-grade gliomas.

scholarly journals Integrin αvβ3–Targeted Dynamic Contrast–Enhanced Magnetic Resonance Imaging Using a Gadolinium-Loaded Polyethylene Gycol–Dendrimer–Cyclic RGD Conjugate to Evaluate Tumor Angiogenesis and to Assess Early Antiangiogenic Treatment Response in a Mouse Xenograft Tumor Model

2012 ◽  
Vol 11 (4) ◽  
pp. 7290.2011.00050 ◽  
Author(s):  
Wei-Tsung Chen ◽  
Tiffany Ting Fang Shih ◽  
Ran-Chou Chen ◽  
Shin-Yang Tu ◽  
Hsieh Wen-Yuen ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Tumor Angiogenesis ◽  
Antiangiogenic Therapy ◽  
Resonance Imaging ◽  
Antiangiogenic Treatment ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced ◽  
Bevacizumab Treatment ◽  
Contrast Enhanced

The purpose of this study was to validate an integrin αvβ3–targeted magnetic resonance contrast agent, PEG-G3-(Gd-DTPA)6-(cRGD-DTPA)2, for its ability to detect tumor angiogenesis and assess early response to antiangiogenic therapy using dynamic contrast–enhanced (DCE) magnetic resonance imaging (MRI). Integrin αvβ3–positive U87 cells and control groups were incubated with fluorescein-labeled cRGD-conjugated dendrimer, and the cellular attachment of the dendrimer was observed. DCE MRI was performed on mice bearing KB xenograft tumors using either PEG-G3-(Gd-DTPA)6-(cRGD-DTPA)2 or PEG-G3-(Gd-DTPA)6-(cRAD-DTPA)2. DCE MRI was also performed 2 hours after anti–integrin αvβ3 monoclonal antibody treatment and after bevacizumab treatment on days 3 and 6t. Using DCE MRI, the 30-minute contrast washout percentage was significantly lower in the cRGD-conjugate injection groups. The enhancement patterns were different between the two contrast injection groups. In the antiangiogenic therapy groups, a rapid increase in 30-minute contrast washout percentage was observed in both the LM609 and bevacizumab treatment groups, and this occurred before there was an observable decrease in tumor size. The integrin αvβ3 targeting ability of PEG-G3-(Gd-DTPA)6-(cRGD-DTPA)2 in vitro and in vivo was demonstrated. The 30-minute contrast washout percentage is a useful parameter for examining tumor angiogenesis and for the early assessment of antiangiogenic treatment response.

Dynamic contrast‐enhanced magnetic resonance imaging for differentiating head and neck paraganglioma and schwannoma

Head & Neck ◽  
2021 ◽  
Author(s):  
Soumya Ranjan Malla ◽  
Ashu Seith Bhalla ◽  
Smita Manchanda ◽  
Devasenathipathy Kandasamy ◽  
Rakesh Kumar ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Head And Neck ◽  
Resonance Imaging ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced ◽  
Head And Neck Paraganglioma
Sign in / Sign up

Export Citation Format

Share Document